Actively Recruiting

Phase 1
Age: 18Years - 80Years
FEMALE
ID06725082

Impact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery in a Multicenter, Randomized, Open-label Trial

Led by Peking University People's Hospital · Updated on 2024-12-10

30

Participants Needed

1

Research Sites

156 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Breast tumors, especially breast cancer, are becoming more common in China with an increasing number of younger patients. Research suggests that Type III Collagen (COL3) plays an important role in protecting tissues and organs within the tumor environment and may slow tumor progression by remodeling this environment. However, no clinical studies have yet explored COL3 in breast tumors. This trial aims to study the effects of locally injecting recombinant humanized Type III Collagen (rhCOL3) during breast tumor surgery to assess its potential benefits and safety. Participants will be randomly assigned to one of two groups: one group will receive injections of rhCOL3 around the tumor before surgery and again around the surgical area skin after confirming safe surgical margins during surgery. The other group will receive saline injections following the same procedure as a control. The rhCOL3 will be given at specific points around the tumor and along the skin incision during surgery. This study is a multicenter, prospective, randomized, open-label, parallel-controlled trial. During the study, participants will be monitored for short-term complications after surgery and radiotherapy over a three-month period. Researchers will also observe changes in clinical pathological indicators related to the tumor. Assessments will include clinical and imaging evaluations, with follow-up visits to track outcomes. The goal is to establish whether local rhCOL3 injection can provide protection and support treatment in breast tumor surgery over both immediate and long-term periods.

CONDITIONS

Brief Title

Impact of Recombinant Humanized Type III Collagen on the Immediate and Long-term Effects of Breast Tumor Surgery

Who Can Participate

Age: 18Years - 80Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Female participants aged 18 to 80 years
  • Clinical and imaging diagnosis of breast tumor with planned needle biopsy
  • Planned breast tumor surgery with possible whole-breast radiotherapy
  • No prior systemic or local anti-tumor treatment before screening
  • ECOG Performance Status of 0 or 1
  • Signed informed consent to join the study
Not Eligible

You will not qualify if you...

  • Bilateral or multiple breast lesions
  • Skin damage or ulceration on the affected breast side
  • Allergy to collagen products or severe allergic constitution
  • History of breast cancer or other malignant tumors
  • Positive pregnancy test or currently breastfeeding
  • Use of anticoagulant, antiplatelet, or non-steroidal anti-inflammatory drugs
  • Severe comorbid diseases such as cardiovascular, blood, autoimmune, neurological, or psychiatric disorders

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Day of surgery

Participants receive injections around the breast tumor and surgical area during surgery, followed by routine tissue flap revision and suture.

1 surgical visit (in-person)

Post-operative Follow-up

Duration - 3 months

Participants are monitored for short-term postoperative complications and changes in clinical pathological indicators after surgery and radiotherapy.

Approximately 3 follow-up visits

Trial Site Locations

Total: 1 location

1

Peking University People's Hospital

Beijing, China, China, 100044

Actively Recruiting

Loading map...

Research Team

M

Mengmeng Zhang

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Similar Trials

Investigating The Role of Key Non-coding RNA(s) in Breast Ca...

Breast Cancer

Actively Recruiting

1 location

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Bre...

Breast Cancer

Actively Recruiting

1 location

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here